• Senseonics entered a partnership with Beta Bionics to integrate the Eversense 365 CGM with the iLet Bionic Pancreas system.
• Integration targets an automated insulin delivery offering built around Eversense’s year-long implantable glucose sensor.
• Development work is expected to finish in Q4 2026.
• Commercial launch is planned for Q4 2026, subject to testing, validation, and regulatory requirements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senseonics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609140700PRIMZONEFULLFEED9825911) on September 14, 2026, and is solely responsible for the information contained therein.